SCHEMBL4481949

SCHEMBL4481949

C=Cc1cc(I)ccc1OCCO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.38
TUBB1 Q9H4B7 2/20 0.37
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ERN1 O75460 1/20 0.34
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
APP P05067 3/20 0.33
RECQL P46063 1/20 0.33
HPGD P15428 1/20 0.32
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
S1PR4 O95977 1/20 0.31
DHPS P49366 1/20 0.30
LMNA P02545 1/20 0.30
LOX P28300 1/20 0.30
AOC3 Q16853 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478679 0.83 ERN1 (0.50) IDO1TUBB1GAAKMT2AKDM4E
SCHEMBL4487594 0.75 F2 (0.44) IDO1KDM4EALDH1A1MAPTHPGD
SCHEMBL4473487 0.75 KDM4E (0.40) IDO1TUBB1GAAKMT2AKDM4E
SCHEMBL4591980 0.75 S1PR4 (0.47) IDO1ALDH1A1MAPTHPGDS1PR4
SCHEMBL14045887 0.75 IDO1 (0.40) IDO1TUBB1GAAKMT2AKDM4E
SCHEMBL4726054 0.74 ALDH1A1 (0.48) IDO1GAAKMT2AKDM4EALDH1A1
SCHEMBL4484005 0.73 IDO1 (0.36) IDO1TUBB1GAAKMT2AKDM4E
SCHEMBL13764926 0.73 TSHR (0.56) GAAKMT2AERN1ALDH1A1MEN1
SCHEMBL20873656 0.72 TUBB1 (0.43) IDO1TUBB1GAAKMT2AKDM4E
SCHEMBL13178752 0.71 TUBB1 (0.42) IDO1TUBB1GAAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 IDO1 684/4885TUBB1 4147/4885GAA 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.